Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABSTRAL vs OBETICHOLIC ACID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Obeticholic acid is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces bile acid synthesis by inhibiting CYP7A1, increases bile acid clearance, and exerts anti-inflammatory and antifibrotic effects.
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults with inadequate response to UDCA, or as monotherapy in adults unable to tolerate UDCA,Off-label: Non-alcoholic steatohepatitis (NASH) with fibrosis (not FDA-approved)
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
5 mg orally once daily, may increase to 10 mg once daily if tolerated after 3 months; maximum dose 10 mg daily.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Terminal elimination half-life is approximately 24 hours (range 14–36 h) in patients with primary biliary cholangitis, allowing once-daily dosing. Steady-state is achieved in about 2 weeks.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Primarily metabolized by glucuronidation via UGT1A1, UGT1A3, and UGT2B7; undergoes enterohepatic recirculation; minimal CYP450 metabolism.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
Primarily biliary, with minimal renal excretion (<3%). The drug and its conjugates are eliminated in feces following biliary secretion. Enterohepatic recirculation occurs.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
≥99% bound to serum proteins, primarily albumin.
4-6 L/kg; large Vd indicates extensive tissue distribution
Approximately 0.2–0.4 L/kg, indicating limited extravascular distribution, consistent with a compound undergoing extensive enterohepatic circulation.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Oral bioavailability is low (~1–2%) due to extensive first-pass metabolism in the liver. Food may reduce absorption.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (e GFR <30 m L/min/1.73 m2) or dialysis; use with caution.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Child-Pugh Class A: No dose adjustment. Child-Pugh Class B or C: Contraindicated.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Safety and efficacy not established in pediatric patients (<18 years).
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
No specific dose adjustment recommended; use standard adult dosing with monitoring for tolerability due to potential age-related decline in hepatic function.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Risk of hepatic decompensation and liver failure in patients with compensated or decompensated cirrhosis (Child-Pugh class B or C). Ocaliva is contraindicated in patients with decompensated cirrhosis or prior hepatic decompensation.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
Hepatic decompensation and liver failure in cirrhotic patients (Child-Pugh class B or C); not recommended in such patients without appropriate dose adjustment.,Severe pruritus: Manage with antihistamines, bile acid resins, or dose reduction.,Elevation of LDL-cholesterol: Monitor lipid levels and manage according to guidelines.,Dose adjustment required for moderate to severe hepatic impairment (Child-Pugh class B and C).
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Complete biliary obstruction,Decompensated cirrhosis (Child-Pugh class B or C) or prior hepatic decompensation,Hypersensitivity to obeticholic acid or any excipients
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
No specific food interactions are reported, but alcohol should be avoided due to potential hepatotoxicity. Bile acid binding resins (e.g., cholestyramine) may reduce absorption; separate administration by at least 4-6 hours.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Animal studies show fetal harm at exposures similar to human therapeutic doses. No adequate human studies. Avoid use in pregnancy unless benefit outweighs risk. First trimester: potential for teratogenicity. Second/third trimester: risk of fetal bile acid toxicity.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
Excretion in human milk unknown. Due to potential for serious adverse reactions in nursing infants, decision should be made to discontinue nursing or drug. M/P ratio not determined.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
No dose adjustment recommendations established. Pregnancy may alter bile acid metabolism; consider lower starting dose due to potential for increased systemic exposure from altered hepatic transport.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Obeticholic acid is a farnesoid X receptor agonist used for primary biliary cholangitis (PBC). It increases bile acid excretion and may cause dose-dependent pruritus; start at 5 mg daily and titrate to 10 mg if tolerated. Monitor hepatic function closely due to risk of liver decompensation. Contraindicated in patients with complete biliary obstruction.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
Take obeticholic acid exactly as prescribed, usually once daily with or without food.,Common side effects include itching (pruritus), which may be severe; inform your doctor if it becomes bothersome.,Report any symptoms of liver problems such as jaundice, dark urine, or abdominal pain immediately.,Avoid alcohol while taking this medication.,Do not take additional bile acid binding resins (e.g., cholestyramine) within 4-6 hours of obeticholic acid.,Inform your healthcare provider of all other medications you are taking, especially warfarin or other blood thinners.,If you are pregnant, planning to become pregnant, or breastfeeding, discuss with your doctor before starting this medication.
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABSTRAL vs OBETICHOLIC ACID, answered by our medical review team.
ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. OBETICHOLIC ACID is a Farnesoid X receptor agonist that works by Obeticholic acid is a potent, selective agonist of the farnesoid X receptor (FXR), a nuclear receptor that regulates bile acid synthesis, transport, and homeostasis. Activation of FXR reduces bile acid synthesis by inhibiting CYP7A1, increases bile acid clearance, and exerts anti-inflammatory and antifibrotic effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABSTRAL and OBETICHOLIC ACID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. The standard adult dose of OBETICHOLIC ACID is: 5 mg orally once daily, may increase to 10 mg once daily if tolerated after 3 months; maximum dose 10 mg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABSTRAL and OBETICHOLIC ACID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. OBETICHOLIC ACID is classified as Category C. Animal studies show fetal harm at exposures similar to human therapeutic doses. No adequate human studies. Avoid use in pregnancy unless benefit outweighs risk. First trimester: po. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.